These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
128 related items for PubMed ID: 3703343
1. [5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma]. Comella G, Mastro AA, Comella P, Castello G, De Simone G, Cerra R, Zarrilli D. Minerva Med; 1986 Mar 31; 77(13):507-10. PubMed ID: 3703343 [No Abstract] [Full Text] [Related]
2. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma. El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R. Surg Gynecol Obstet; 1978 Feb 31; 146(2):230-2. PubMed ID: 622668 [Abstract] [Full Text] [Related]
3. [Radical cystectomy for superficial tumors in the BCG era]. Huguet Pérez J, Palou J, Millán Rodríguez F, Villavicencio Mavrich H, Rodríguez JV. Arch Esp Urol; 2002 Feb 31; 55(1):50-6. PubMed ID: 11957752 [Abstract] [Full Text] [Related]
4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL. BJU Int; 2009 Jul 31; 104(2):179-83. PubMed ID: 19154448 [Abstract] [Full Text] [Related]
5. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma]. Calbo L, Gorgone S, Palmeri R, Salibra M, Melita P. Chir Ital; 1983 Aug 31; 35(4):519-25. PubMed ID: 6680859 [Abstract] [Full Text] [Related]
6. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Cancer; 2004 Apr 15; 100(8):1692-8. PubMed ID: 15073858 [Abstract] [Full Text] [Related]
7. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma]. Kretschmer L, Helmbold P, Emmert S, Marsch WC. Hautarzt; 2002 Aug 15; 53(8):536-41. PubMed ID: 12221468 [Abstract] [Full Text] [Related]
8. Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy. Paterson AH, McPherson TA, Willans DJ. Cancer Treat Rep; 1978 Apr 15; 62(4):571-3. PubMed ID: 350395 [No Abstract] [Full Text] [Related]
9. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association. Int J Urol; 2009 Mar 15; 16(3):279-86. PubMed ID: 19207609 [Abstract] [Full Text] [Related]
10. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Silver HK, Ibrahim EM, Evers JA, Thomas JW, Murray RN, Spinelli JJ. Can Med Assoc J; 1983 Jun 01; 128(11):1291-5. PubMed ID: 6342739 [Abstract] [Full Text] [Related]
11. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Ann Surg; 1985 Jan 01; 201(1):103-7. PubMed ID: 3966826 [Abstract] [Full Text] [Related]
12. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S. Eur J Surg Oncol; 2009 Apr 01; 35(4):352-5. PubMed ID: 18722076 [Abstract] [Full Text] [Related]
13. The optimal management of T1G3 bladder cancer. Emiliozzi P, Pansadoro A, Pansadoro V. BJU Int; 2008 Nov 01; 102(9 Pt B):1265-73. PubMed ID: 19035891 [No Abstract] [Full Text] [Related]
14. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma]. Korting HC, Strasser S, Konz B. Hautarzt; 1988 Mar 01; 39(3):170-3. PubMed ID: 3378889 [Abstract] [Full Text] [Related]
15. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study]. Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I. Aktuelle Urol; 2009 Mar 01; 40(2):91-9. PubMed ID: 19214951 [Abstract] [Full Text] [Related]
16. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine]. Bretheau D, Lechevallier E, Rossi D, Albert P, de Fromont M, Coulange C. Prog Urol; 1993 Mar 01; 3(4):608-17. PubMed ID: 8401621 [Abstract] [Full Text] [Related]
17. [Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer]. Yang DA, Li SQ, Li XT. Zhonghua Wai Ke Za Zhi; 1994 Jul 01; 32(7):433-4. PubMed ID: 7842985 [Abstract] [Full Text] [Related]
18. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG]. Ayed M, Ben Hassine L, Ben Slama R, Chelbi N, Ghozzi S, Drissi H, Jemni M, Chebil M. Prog Urol; 1998 Apr 01; 8(2):206-10. PubMed ID: 9615929 [Abstract] [Full Text] [Related]
19. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J; 1983 Apr 15; 128(8):929-33. PubMed ID: 6339024 [Abstract] [Full Text] [Related]
20. [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract]. An JS, Wu LY, Li N, Li B, Yu GZ, Liu LY. Zhonghua Fu Chan Ke Za Zhi; 2007 May 15; 42(5):320-4. PubMed ID: 17673044 [Abstract] [Full Text] [Related] Page: [Next] [New Search]